267 related articles for article (PubMed ID: 37622116)
61. Role of cuproptosis-related gene in lung adenocarcinoma.
Liu Y; Lin W; Yang Y; Shao J; Zhao H; Wang G; Shen A
Front Oncol; 2022; 12():1080985. PubMed ID: 36620594
[TBL] [Abstract][Full Text] [Related]
62. A novel cuproptosis-related signature predicts prognosis and immunotherapy efficacy in lung adenocarcinoma.
Cui Y; Zhang LJ; Xu YJ; Liu MY
Am J Transl Res; 2023; 15(6):3942-3959. PubMed ID: 37434829
[TBL] [Abstract][Full Text] [Related]
63. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract][Full Text] [Related]
64. Development and validation of an immune-related prognostic signature in lung adenocarcinoma.
Sun S; Guo W; Wang Z; Wang X; Zhang G; Zhang H; Li R; Gao Y; Qiu B; Tan F; Gao Y; Xue Q; Gao S; He J
Cancer Med; 2020 Aug; 9(16):5960-5975. PubMed ID: 32592319
[TBL] [Abstract][Full Text] [Related]
65. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
Li Y; Zeng X
Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
[No Abstract] [Full Text] [Related]
66. The role of radiotherapy-related autophagy genes in the prognosis and immune infiltration in lung adenocarcinoma.
Gao J; Lu F; Yan J; Wang R; Xia Y; Wang L; Li L; Chang L; Li W
Front Immunol; 2022; 13():992626. PubMed ID: 36311724
[TBL] [Abstract][Full Text] [Related]
67. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
Front Genet; 2023; 14():1096783. PubMed ID: 36911392
[No Abstract] [Full Text] [Related]
68. Construction and validation of a cuproptosis-related lncRNA signature for the prediction of the prognosis of LUAD and LUSC.
Wang Y; Xiao X; Li Y
Sci Rep; 2023 Feb; 13(1):2477. PubMed ID: 36774418
[TBL] [Abstract][Full Text] [Related]
69. Development of metastasis-associated seven gene signature for predicting lung adenocarcinoma prognosis using single-cell RNA sequencing data.
He J; Zhang W; Li F; Yu Y
Math Biosci Eng; 2021 Jul; 18(5):5959-5977. PubMed ID: 34517518
[TBL] [Abstract][Full Text] [Related]
70. Molecular subtypes based on cuproptosis-related genes and immune profiles in lung adenocarcinoma.
Wang Y; Zhang C; Ji C; Jin W; He X; Yu S; Guo R
Front Genet; 2022; 13():1006938. PubMed ID: 36313439
[No Abstract] [Full Text] [Related]
71. An
Han Y; Wong FC; Wang D; Kahlert C
Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555
[TBL] [Abstract][Full Text] [Related]
72. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
73. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
74. A seven-gene prognostic model related to immune checkpoint PD-1 revealing overall survival in patients with lung adenocarcinoma.
Niu W; Jiang L
Math Biosci Eng; 2021 Jul; 18(5):6136-6154. PubMed ID: 34517527
[TBL] [Abstract][Full Text] [Related]
75. A Novel Immune-Related Gene Signature Predicts Prognosis of Lung Adenocarcinoma.
Ma C; Li F; Wang Z; Luo H
Biomed Res Int; 2022; 2022():4995874. PubMed ID: 35437508
[TBL] [Abstract][Full Text] [Related]
76. Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: development and validation based on TCGA and ICGC databases.
Ma Q; Hui Y; Huang BR; Yang BF; Li JX; Fan TT; Gao XC; Ma DY; Chen WF; Pei ZX
Transl Cancer Res; 2023 Jan; 12(1):46-64. PubMed ID: 36760376
[TBL] [Abstract][Full Text] [Related]
77. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
[TBL] [Abstract][Full Text] [Related]
78. Construction of cuproptosis-related gene signature to predict the prognosis and immunotherapy efficacy of patients with bladder cancer through bioinformatics analysis and experimental validation.
Liu Z; Zhu F; Zhang P; Qian B; Liu W; Xiao Y; Chen N; He Q; Xiao J
Front Genet; 2022; 13():1074981. PubMed ID: 36506302
[No Abstract] [Full Text] [Related]
79. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer.
Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X
Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537
[TBL] [Abstract][Full Text] [Related]
80. Identification and integration analysis of a novel prognostic signature associated with cuproptosis-related ferroptosis genes and relevant lncRNA regulatory axis in lung adenocarcinoma.
Wang T; Jiang X; Lu Y; Ruan Y; Wang J
Aging (Albany NY); 2023 Mar; 15(5):1543-1563. PubMed ID: 36881404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
